Atual distribuição geográfica dos moluscos hospedeiros intermediários do Schistosoma mansoni em Belo Horizonte, MG, Brasil

Procedeu-se ao levantamento malacológico do município de Belo Horizonte, MG, com o objetivo de avaliar a distribuição, densidade e taxa de infecção dos moluscos hospedeiros intermediários do Schistosoma mansoni. Foram coletadas 3.261 Biomphalaria glabrata em 1979-81, das quais 100 (3,1%) estavam infectadas com S. mansoni. Registrou-se a existência de 36 criadouros (35,0%) de B. glabrata em 102 locais pesquisados, sendo 23 na bacia hidrográfica de Pampulha e 13 na do ribeirão do Arrudas. Foram encontrados 2 criadouros de B. tenagophila e 2 de B. straminea. Registrou-se também a presenca de exemplares de Pomacea haustrum, Physa sp e Drepanotrema cimex. Compararam-se os dados obtidos atualmente com os publicados em 1967. Houve reducao de mais de 50% no número de criadouros de B.glabrata, principalmente em decorrencias da expansão e progresso da cidade. Na zona periférica a esquistossomose continua endêmica, havendo necessidade de novas obras de saneamento básico para se conseguir o controle da doença.

Ectoparasitos de roedores da região urbana de Belo Horizonte, MG. I. Interação entre ectoparasitos e hospedeiros

Um levantamento de ectoparasitos de roedores domesticos da região urbana de Belo Horizonte, Minas Gerais, Brasil, foi realizado no período de junho de 1980 a setembro de 1982. As espécies de ectoparasitos capturadas de 950 Rattus norvegicus foram: Xenopsylla cheopis, Ctenocephalides felis felis, Polyplax spinulosa, Laelaps nuttalli, Eschinolaelaps echidninus e Atricholaelaps glasgowi, esta ultima apenas representada por três exemplares intercambiados com roedores silvestres. As espécies P. spinulosa e L. nuttalli, embora cosmopolitas, sao registradas pela primeira vez no Estado de Minas Gerais. A relação entre os sexos dos ectoparasitos bem como a prevalência de pulgas, ácaros e piolho por sexos separados de roedores são apresentadas. 66,9% dos roedores estavam infestados por ácaros, quase duas vezes mais do que as infestações por pulgas e piolho conjuntamente (39%). L. nuttalli foi a espécie mais numerosa e a que apresentou o maior índice de infestação: 55,1%. As infestações simples e associadas se equivaleram numericamente. P. spinulosa, ao contrário de L. nuttalli, raramente ocorreu em infestações simples. Dados sobre a distribuição dos ectoparasitos nos roedores sao também assinalados. A infestação observada em Belo Horizonte e confrontada com aquelas obtidas por outros autores em algumas cidades do mundo.

Desenvolvimento das gônadas de Dermatobia hominis (Diptera: Cuterebridae)

O trabalho descreve o desenvolvimento das gônadas do berne (D. hominis) durante o período pupal. As pupas desenvolvidas de larvas com peso superior a 650 mg, deram imagos fêmeas, enquanto que as desenvolvidas daquelas pesando entre 500 e 650 mg deram macho, tendo havido um erro ao redor de 5%. Até o oitavo dia de pupação os testículos crescem mais que os ovários; a partir daí diminui o desenvolvimento, parando de crescer entre o vigésimo e vigésimo quinto dias. A espermatogênese inicia por volta do sétimo dia de pupa quando é grande o número de espermatócitos. No décimo dia alguns testículos apresentam considerável número de espermátides e os espermatozóides começam a aparecer por volta do vigésimo dia. A espermiogênese desenvolve-se sem interrupção e ao final da pupação quase toda loja testicular está repleta de espermatózóides. Os machos começam a nascer dois dias antes das fêmeas. Nessas, os ovaríolos aparecem formados por volta do oitavo dia de pupa; os folículos se individualizam por volta do vigésimo dia de pupa onde se distingue os trofócitos com núcleos politênicos e citoplasmas bem basófilos, enquanto o ovócito tem citoplasma mais acidófilo e núcleo com cromatina bastante frouxa. A vitelogênese tem início ao redor do vigésimo quinto dia de pupa e se completa ao nascimento da imago. A ligação das gônadas com suas respectivas estruturas somáticas acontece ao redor do décimo terceiro dia de pupação.

Características físicas e químicas do habitat da Biomphalaria tenagophila (Mollusca, Planorbidae)

Foram realizadas mensalmente, através de conchadas aleatórias, coletas de caramujos e de água, em uma pequena represa, visando a contribuir para o conhecimento das características físico-químicas da água e sua possível influência sobre alguns parâmetros, biológicos. Dos 17 fatores analisados, a Alcalinidade e a Condutividade se mostraram positivamente correlacionadas com a densidade de B. tenagophila (r = +0,224 e +0,290), enquanto que CO2 e Acidez se correlacionaram negativamente com densidade (r = -0,592 e -0,601). Alcalinidade e Dureza Total apresentaram valores um pouco acima de 100 mg/l de CaCO3; Condutividade e Cloretos, teores considerados altos para a região (680,1 ± 64,3micronS/cm e 94,9 ± 38,7 mg/l). Os demais fatores, como pH e OD, estiveram dentro dos padrões de águas brutas de abastecimento. As densidades de B. tenagophila foram mais baixas nos seis meses subseqüentes a um longo período de chuvas tortenciais (12 a 30 caramujos/ 90 conchadas/mês) e nos verões chuvosos. Nos meses mais frios de 1980 foram mais elevadas. Os diâmetros médios mensais foram sempre superiores a 13 mm, chegando a 21,4 ± 4,1 mm; mas a média da maioria dos meses girou em torno de 17 mm. Não houve correlação diâmetro/densidade (r = 0,037), nem densidade/temperatura (r = 0,065).

Efficacy of ivermectin against the bloodsucking insect, Rhodnius prolixus (Hemiptera, Triatominae)

Ivermectin (0.2 mg/kg body weight) caused a high mortality in nymphs and adults of Rhodnius prolixus following a single meal in mice sub-cutaneously injected with the drug. This effect was more evident in nymphs of 1st-and 2nd-instar than in older nymphs and adults. Third-instar nymphs presented a high mortality when fed on mice treated with ivermectin 24 and 48 hours previously, while mortality was significantly reduced in nymphs fed on mice treated 72 hours before. Surviving 3rd-instar nymphs did not molt. When adult females were fed once on mice treated for 24 hours with ivermectin there was a considerable reduction in egg production. This inhibition was not reversed by a second feeding on normal mice. We concluded that sub-lethal doses of ivermectin caused toxic effects interfering in the neuro-endocrine control of development and reproduction of this bloodsucking insect.

Potencialidade de Biomphalaria tenagophila do lago Pampulha, Belo Horizonte, MG, como hospederia do Schistosoma mansoni

Caramujos Biomphalaria tenagophila descendentes de exemplares coletados no lago da Pampulha, Belo Horizonte, Minas Gerais, foram expostos a miracídios de quatro cepas de Schistosoma mansoni: LE e HK de origem local, Belo Horizonte, AL do Estado de Alagoas e SJ, de São José dos Campos, SP. As cepas LE, AL e SJ são mantidas em laboratório e HK foi obtida de fezes de paciente que reside próximo à Pampulha. As taxas de infecção experimental foram de 4% (LE), 6% (HK), 30% (SJ) e 40% (AL). Esses indícios de infecção foram semelhantes aos obtidos por vários autores para populações de B. tenagophila de Minas Gerais. Caramujos infectados experimentalmente eliminaram número de cercárias comparável ao de B. glabrata do controle e de B. tenagophila capturada no lago, com infecção natural (cerca de 2.000 cercárias/molusco). Devido à alta densidade planorbídica atual em alguns pontos do lago, número de cercárias eliminadas por exemplares naturalmente infectados, afluxo de pessoas para pesca e lazer, contaminação das águas por dejetos humanos, os autores alertam para o risco de crescimento do foco de esquistossomose no local.

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.

BACKGROUND: Lipid-lowering therapy is costly but effective at reducing coronary heart disease (CHD) risk. OBJECTIVE: To assess the cost-effectiveness and public health impact of Adult Treatment Panel III (ATP III) guidelines and compare with a range of risk- and age-based alternative strategies. DESIGN: The CHD Policy Model, a Markov-type cost-effectiveness model. DATA SOURCES: National surveys (1999 to 2004), vital statistics (2000), the Framingham Heart Study (1948 to 2000), other published data, and a direct survey of statin costs (2008). TARGET POPULATION: U.S. population age 35 to 85 years. Time Horizon: 2010 to 2040. PERSPECTIVE: Health care system. INTERVENTION: Lowering of low-density lipoprotein cholesterol with HMG-CoA reductase inhibitors (statins). OUTCOME MEASURE: Incremental cost-effectiveness. RESULTS OF BASE-CASE ANALYSIS: Full adherence to ATP III primary prevention guidelines would require starting (9.7 million) or intensifying (1.4 million) statin therapy for 11.1 million adults and would prevent 20,000 myocardial infarctions and 10,000 CHD deaths per year at an annual net cost of $3.6 billion ($42,000/QALY) if low-intensity statins cost $2.11 per pill. The ATP III guidelines would be preferred over alternative strategies if society is willing to pay $50,000/QALY and statins cost $1.54 to $2.21 per pill. At higher statin costs, ATP III is not cost-effective; at lower costs, more liberal statin-prescribing strategies would be preferred; and at costs less than $0.10 per pill, treating all persons with low-density lipoprotein cholesterol levels greater than 3.4 mmol/L (>130 mg/dL) would yield net cost savings. RESULTS OF SENSITIVITY ANALYSIS: Results are sensitive to the assumptions that LDL cholesterol becomes less important as a risk factor with increasing age and that little disutility results from taking a pill every day. LIMITATION: Randomized trial evidence for statin effectiveness is not available for all subgroups. CONCLUSION: The ATP III guidelines are relatively cost-effective and would have a large public health impact if implemented fully in the United States. Alternate strategies may be preferred, however, depending on the cost of statins and how much society is willing to pay for better health outcomes. FUNDING: Flight Attendants' Medical Research Institute and the Swanson Family Fund. The Framingham Heart Study and Framingham Offspring Study are conducted and supported by the National Heart, Lung, and Blood Institute.

Bioquímica da esquistossomose mansônica: VII. Alterações lipídicas das membranas lisossômicas durante a faze inicial da agressão hepática

Com o intuito de se estudarem as alterações nos teores lipídicos, constituintes das membranas lisossômicas, em fígados, durante a fase inicial da agressão esquistossomótica, foram utilizados camundongos infectados com 30 cercárias e 30 dias de infecção. Os triaglicerídios passaram de 200 ± 48 µg/mg de proteínas totais nos controles, para 165 ± 22 µg/mg, nos infectados. Na mesma ordem também diminuiram o colesterol livre de 539 ± 80, para 396 ± 54 µg/mg; os ésteres do colesterol de 270 ± 35, para 216 ± 36 µg/mg e os colinafosfatídios de 44 ± 5,7 para 31 ± 4,9 µg/mg. Os serinafosfatídios, os etanolaminafosfatídios e os esfingofosfatídios aumentaram, respectivamente de 58 ± 9,7 para 60 ± 8,5, de 72 ± 7,8 para 111 ± 15,7 e de 36 ± 4,9 para 63 7,1 µg/mg. Os ácidos graxos livres não se alteram significativamente, passaram de 1,7 ± 0,35 µEq/g, nos controles, para 1,8 ± 0,29 Eq/g nos animais infectados. Esses resultados padecem indicar que na fase inicial de esquistossomose mansônica hepática, antes da formação dos granulomas, são detectadas alterações importantes na constituição lipídica das membranas do compartimento lisossônico. Elas, talvez, sejam devidas a produtos catabólicos, excretados por vermes imaturos ou adultos, presentes em vasos do sistema portal.

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).

BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment. PATIENTS AND METHODS: This is a phase II, open, multicenter, noncomparative study. Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease. Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days. RESULTS: All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases. Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B. Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B. CONCLUSIONS: Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy. Prior response to an AI did not appear to be predictive for benefit with fulvestrant.

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.

Background: Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based patients. Methods: Baseline and Week 6 evaluation questionnaires were sent to all Swiss gastroenterologists in hospitals and private practices. Disease activity was assessed with the Harvey-Bradshaw Index (HBI) and adverse events were evaluated according to WHO guidelines. Results: Fifty patients (31 women, 19 men) were included; 56% had complicated disease (stricture or fistula) and 52% had undergone prior CD-related surgery. All patients. had prior exposure to systemic steroids, 96% to immunomodulators, 78% to infliximab, and 50% to adalimumab. A significant decrease in HBI was observed at Week 6 (versus Week 0) following induction therapy with CZP 400 mg subcutaneously at Weeks 0, 2, and 4 (12.6 +/- 4.7 Week 0 versus 6.2 +/- 4.4 Week 6, P < 0.001). Response and remission rates at Week 6 were 54% and 40%, respectively. We identified 8/11 CD patients undergoing a 50% fistula response (P = 0.021). The frequency of adverse drug reactions attributed to CZP was 6%. CZP was continued in 80% of patients beyond Week 6. Conclusions: In a population of CD patients with complicated disease behavior, CZP induced a response and remission in 54% and 40% of patients, respectively. This series provides the first evidence of the effectiveness of CZP in perianal fistulizing CD.

Infecção natural das glândulas anais de gambás (Didelphis albiventris) pelo Trypanosoma cruzi no município de Bambuí - MG

De 87 gambás, Didelphis albiventris, capturados na região de Bambuí (MG), 32 (36,7%) estavam infectados pelo Trypanosoma cruzi. Os índices de infecção foram 34,9%, 81,8% e 7,7%, respectivamente, para animais capturados em ambiente silvestre, peridomiciliar rural e periodomiciliar urbano. Em 20 gambás infectados as glândulas anais foram examinadas repetidamente e apenas um (5%) animal (GA09) apresentou exame positivo. Foram positivos 7 dos 17 exames a fresco da secreção glandular desta animal ao longo de 18 meses. Material destas glândulas produziu parasitemia patente em gambás e infecção subpatente em camundongos. A análise isoenzimática realizada com amostras de T. cruzi do GA09, obtidas via hemocultura, xenodiagnóstico e glândulas anais demonstraram pertencerem rigorosamente ao mesmo Zimodema semelhante ao Zimodema Z1. As observações mostram que a infecção das glândulas anias pelo T. cruzi em gambás naturalmente infectados da região de Bambuí é baixa.

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.

BACKGROUND: We conducted a randomized, phase II, multicenter study to evaluate the anti-epidermal growth factor receptor (EGFR) mAb panitumumab (P) in combination with chemoradiotherapy (CRT) with standard-dose capecitabine as neoadjuvant treatment for wild-type KRAS locally advanced rectal cancer (LARC). PATIENTS AND METHODS: Patients with wild-type KRAS, T3-4 and/or N+ LARC were randomly assigned to receive CRT with or without P (6 mg/kg). The primary end-point was pathological near-complete or complete tumor response (pNC/CR), defined as grade 3 (pNCR) or 4 (pCR) histological regression by Dworak classification (DC). RESULTS: Forty of 68 patients were randomly assigned to P + CRT and 28 to CRT. pNC/CR was achieved in 21 patients (53%) treated with P + CRT [95% confidence interval (CI) 36%-69%] versus 9 patients (32%) treated with CRT alone (95% CI: 16%-52%). pCR was achieved in 4 (10%) and 5 (18%) patients, and pNCR in 17 (43%) and 4 (14%) patients. In immunohistochemical analysis, most DC 3 cells were not apoptotic. The most common grade 805;3 toxic effects in the P + CRT/CRT arm were diarrhea (10%/6%) and anastomotic leakage (15%/4%). CONCLUSIONS: The addition of panitumumab to neoadjuvant CRT in patients with KRAS wild-type LARC resulted in a high pNC/CR rate, mostly grade 3 DC. The results of both treatment arms exceeded prespecified thresholds. The addition of panitumumab increased toxicity.

Nitric oxide synthase 2 is required for conversion of pro-fibrogenic inflammatory CD133+ progenitors into F4/80+ macrophages in experimental autoimmune myocarditis.

AIMS: Experimental autoimmune myocarditis (EAM) model mirrors important mechanisms of inflammatory dilated cardiomyopathy (iDCM). In EAM, inflammatory CD133(+) progenitors are a major cellular source of cardiac myofibroblasts in the post-inflammatory myocardium. We hypothesized that exogenous delivery of macrophage-colony-stimulating factor (M-CSF) can stimulate macrophage lineage differentiation of inflammatory progenitors and, therefore, prevent their naturally occurring myofibroblast fate in EAM. METHODS AND RESULTS: EAM was induced in wild-type (BALB/c) and nitric oxide synthase 2-deficient (Nos2(-/-)) mice and CD133(+) progenitors were isolated from inflamed hearts. In vitro, M-CSF converted inflammatory CD133(+) progenitors into nitric oxide-producing F4/80(+) macrophages and prevented transforming growth factor-β-mediated myofibroblast differentiation. Importantly, only a subset of heart-infiltrating CD133(+) progenitors expresses macrophage-specific antigen F4/80 in EAM. These CD133(+)/F4/80(hi) cells show impaired myofibrogenic potential compared with CD133(+)/F4/80(-) cells. M-CSF treatment of wild-type mice with EAM at the peak of disease markedly increased CD133(+)/F4/80(hi) cells in the myocardium, and CD133(+) progenitors isolated from M-CSF-treated mice failed to differentiate into myofibroblasts. In contrast, M-CSF was not effective in converting CD133(+) progenitors from inflamed hearts of Nos2(-/-) mice into macrophages, and M-CSF treatment did not result in increased CD133(+)/F4/80(hi) cell population in hearts of Nos2(-/-) mice. Accordingly, M-CSF prevented post-inflammatory fibrosis and left ventricular dysfunction in wild-type but not in Nos2(-/-) mice. CONCLUSION: Active and NOS2-dependent induction of macrophage lineage differentiation abrogates the myofibrogenic potential of heart-infiltrating CD133(+) progenitors. Modulating the in vivo differentiation fate of specific progenitors might become a novel approach for the treatment of inflammatory heart diseases.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)